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PAWS1 controls Wnt signalling through association
with casein kinase 1a
Polyxeni Bozatzi1,†, Kevin S Dingwell2,†, Kevin ZL Wu1, Fay Cooper2, Timothy D Cummins1,
Luke D Hutchinson1, Janis Vogt1, Nicola T Wood1, Thomas J Macartney1, Joby Varghese1,
Robert Gourlay1, David G Campbell1, James C Smith2,* & Gopal P Sapkota1,**
Abstract
The BMP and Wnt signalling pathways determine axis specification
during embryonic development. Our previous work has shown that
PAWS1 (also known as FAM83G) interacts with SMAD1 and modu-
lates BMP signalling. Here, surprisingly, we show that overexpres-
sion of PAWS1 in Xenopus embryos activates Wnt signalling and
causes complete axis duplication. Consistent with these observa-
tions in Xenopus, Wnt signalling is diminished in U2OS osteosar-
coma cells lacking PAWS1, while BMP signalling is unaffected. We
show that PAWS1 interacts and co-localises with the a isoform of
casein kinase 1 (CK1), and that PAWS1 mutations incapable of
binding CK1 fail both to activate Wnt signalling and to elicit axis
duplication in Xenopus embryos.
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Introduction
PAWS1 (protein associated with Smad1) interacts with Smad1, an
intracellular mediator of bone morphogenetic protein (BMP) signal-
ling, and in particular, it modulates SMAD4-independent BMP activ-
ity [1]. The protein is conserved in vertebrates, and it belongs to the
poorly characterised FAM83 family (FAMily with sequence similar-
ity 83; FAM83A-H), which is defined by an N-terminal DUF1669
domain of unknown function and contains a pseudo-phospholipase
D catalytic motif [2]. Beyond the DUF1669 domain, there is no
sequence similarity between FAM83 members [1,3]. There are two
known conditions mapped to mutations in FAM83G. In mice, the
wooly mutation (wly), which results in a matted and rough coat in
3- to 4-week-old pups, is due to aberrant splicing of PAWS1 result-
ing in a severely truncated protein [4]. The second is a recessive
missense mutation (p.R52P) within the DUF1669 domain of
FAM83G in dogs suffering from hereditary footpad hyperkeratosis
(HFH) [5]. The affected dogs develop hard and cracked footpads
that over time become severely debilitating [5]. However, our
knowledge of the molecular function of FAM83G/PAWS1 is limited.
BMP signalling plays important roles in development and in
adult tissue homeostasis. In the developing Xenopus embryo, a
gradient of BMP activity helps pattern the dorso-ventral axis, with
the highest levels of BMP signalling promoting formation of the
most ventral tissues [6,7]. In an effort to explore the function of
PAWS1 in more detail, we overexpressed the protein in early Xeno-
pus embryos. To our surprise, PAWS1 did not cause embryos to be
ventralised but instead induced complete secondary axes, including
well-formed heads. Such a response is typically obtained after
ectopic activation of the Wnt signalling pathway [8], and we con-
firmed both in Xenopus and in U2OS osteosarcoma cells that PAWS1
does regulate Wnt signalling.
Mass spectrometric analysis revealed that PAWS1 interacts with
casein kinase 1, and we show that this association is critical for
PAWS1 to impact Wnt signalling in cells and embryos.
Results
PAWS1 induces the formation of a secondary axis in
Xenopus embryos
In an effort to explore the biological activity of PAWS1, we injected
500 pg of mRNA encoding Xenopus PAWS1 into the animal hemi-
spheres of Xenopus embryos at the one-cell stage. Such embryos
went on to display axial defects, including dorsalisation and the
formation of partial secondary axes (Fig EV1A–C). To explore this
phenomenon in more detail, we injected a single ventral blastomere
at the four-cell stage with xPAWS1 mRNA. Such embryos went on
to form complete secondary axes, resembling those formed in
response to ectopic xWnt8 (Fig 1A and B). Similar results were
obtained with human PAWS1 (hPAWS1; Fig 1C).
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Early UV exposure of Xenopus embryos inhibits cortical rotation
and prevents formation of a dorsal inducing centre [9]. UV-
ventralised embryos of this sort can be rescued by ectopic activation
of the Wnt signalling pathway [10–13], and consistent with its
strong dorsalising activity, we found that xPAWS1 is indeed able to
rescue UV-treated embryos (Fig 1D).
A
D
E
F
B C
Figure 1. PAWS1 causes axis duplication in Xenopus embryos.
A Representative images of an uninjected embryo, and embryos injected with 250 pg xPAWS1 mRNA or 5 pg xWnt8 mRNA. Scale bars are 1 mm.
B Quantification of (A). Complete axis denotes embryos with a secondary axis with a cement gland, while a partial axis does not.
C Quantification of axis-inducing activity of 250 pg of hPAWS1.
D 250 pg of xPAWS1 mRNA rescues UV-ventralised embryos.
E xPAWS1 induces dorsal and represses ventral gene expression in the whole embryo. A single blastomere at the four-cell stage was injected with either 200 pg nuclear
b-gal mRNA alone or with 250 pg of xPAWS1 and 200 pg of nuclear b-gal mRNA. At stage 10, embryos were fixed, stained for b-gal and then developed for in situ
hybridisation using probes specific for Chordin or Vent2. In dorsal blastomeres, xPAWS1 induces expression of Chordin, while in ventral blastomeres it represses Vent2
expression. The number of embryos tested is indicated. Scale bars are 500 lm.
F 250 pg of xPAWS1 and 200 pg of CFP_gpi mRNAs was injected into the marginal zone of each blastomere at the four-cell stage. The dorsal/ventral (D/V) and animal/vegetal
(A/V) axes are indicated. At stage 10, the dorsal marginal zone (DMZ) and ventral marginal zone (VMZ) were isolated and dorsal and ventral marker expression was assessed
by qPCR. xPAWS1 inhibits ventral marker expression (Msx-1 and Vent2), while concomitantly upregulating the dorsal markers Chordin and Siamois in the VMZ. Expressions of
Msx-1, Vent2, Siamois, and Chordin were normalised to the expression levels of Histone H4, and presented as a fold change with respect to the average levels in whole
embryos (WE), (n = 8, error bars represent  SEM; t-test, unpaired, two-tailed with unequal variance Mann–Whitney test, P-values are as indicated).
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We also examined gene expression in the early embryo following
xPAWS1 overexpression. When injected into the marginal zone,
xPAWS1 suppressed expression of the ventral genes Msx1 (Fig 1F),
and Vent2 in the ventral marginal zone (VMZ; Fig 1E and F), and
increased expression of dorsal markers Siamois (Fig 1F), and
Chordin (Fig 1E and F). Together, these results suggest that PAWS1
promotes Wnt signalling.
PAWS1 does not inhibit canonical BMP signalling
Components of the Wnt signal transduction pathway can induce the
formation of a complete secondary axis in Xenopus [14–17].
However, inhibition of BMP signalling can induce partial secondary
axes [18], and it is possible that as a SMAD1-interacting protein,
PAWS1 might also exert some effects by inhibiting BMP signalling.
However, xPAWS1 did not inhibit BMP-induced nuclear transloca-
tion of SMAD1 in dissociated animal cap cells, nor did it affect
expression of the BMP responsive ventral genes Msx1 and Vent1
(Fig 2A and B). Together, these data suggest that the ability of
PAWS1 to induce secondary axes occurs solely through the Wnt
pathway.
Consistent with this conclusion, we showed previously that the
introduction of PAWS1 in PC3 prostate cancer cells (that normally
do not express PAWS1) does not affect BMP-induced phosphoryla-
tion of SMAD1, nor the transcription of SMAD4-dependent BMP
target genes [1]. Similarly, BMP-induced phosphorylation of SMAD1
in PAWS1/ U2OS cells created by CRISPR/Cas9 genome editing
[19] resembles that in wild-type U2OS cells as well as that in
PAWS1/ cells in which PAWS1 has been restored (Fig 2C). The
same is true for TGFb-induced phosphorylation of SMAD2/3 in the
three cell lines (Fig 2C). Thus, PAWS1 has no significant effect on
canonical BMP signalling in Xenopus embryos and nor in human
cells.
PAWS1 enhances canonical Wnt signalling in Xenopus embryos
and human cells
Our data suggest that PAWS1 activates Wnt signalling. To confirm
this, we tested its ability to stabilise GFP-tagged b-catenin in Xeno-
pus animal pole regions. GFP fluorescence was undetectable in
animal pole cells derived from embryos injected with 50 pg mRNA
encoding b-catenin-GFP, either by Western blot (Fig 3A and C) or
by confocal imaging (Figs 3E and EV1D, F and G). Some stabilised
b-catenin-GFP was detectable after treatment of caps with the Wnt
agonist CHIR99021 (Fig EV1E, H and I). Approximately ten times
more b-catenin-GFP was present in animal caps co-expressing
xPAWS1 (Fig 3A and C), some of which was in an active unphos-
phorylated state (Fig 3A and C). b-Catenin-GFP could also be
detected by confocal microscopy in the nuclei of dissociated animal
cap cells (Fig 3E). Levels of endogenous and active b-catenin also
A B
C
Figure 2. BMP signalling pathway is not affected by PAWS1.
A Expression of pSMAD1 in dissociated animals cap cells. Embryos were injected into the animal pole of both blastomeres at the two-cell stage with a total of either
1 ng of BMP4 or 1 ng BMP4 and 500 pg of Myc-tagged(MT)xPAWS1 mRNAs. Dissociated cells were stained with antibodies against MYC-tag (xPAWS1, green) and for
phospho-SMAD1 (p-SMAD1, red). Scale bars are 50 lm.
B Expression of ventral markers in animal caps cells injected at the two-cell stage with a total of either 1 ng of BMP4 or 1 ng BMP4 and 500 pg of MTxPAWS1 mRNA
(n = 3, error bars represent  SD, ns—not significant, t-test, unpaired, two-tailed with unequal variance).
C U2OS wild-type (WT), PAWS1/ and PAWS1WT rescue cells were serum-deprived for 16 h. Cells were subsequently stimulated with either 6.25 ng/ml BMP2 or 50 pM
TGFb1 for 1 h prior to lysis. Cell extracts (15 lg) were resolved by SDS–PAGE and immunoblotted with the indicated antibodies. Note that the upper band in the
P-SMAD3 blot is a result of the antibody cross-reacting with P-SMAD1.
Source data are available online for this figure.
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increased following injection of xPAWS1 mRNA into naı¨ve animal
caps (Fig 3B and D). Finally, animal caps expressing xPAWS1 acti-
vated the direct Wnt target Siamois [20–22] and the dorsalising
factor Chordin [18], confirming that PAWS1 can activate the canoni-
cal Wnt pathway (Fig 3F). We mapped the domain of PAWS1 that
is required for Wnt signalling by testing the ability of different
PAWS1 fragments to induce secondary axes in Xenopus and to acti-
vate Siamois expression in animal caps (Fig 3G–I). The DUF1669
domain proved to be necessary but not sufficient to activate canoni-
cal Wnt signalling, while the 583 fragment that displays activity
suggests that the conserved BMPR1 phosphorylation sites S610, S613
and S614 do not impact activity (Fig 3G–I). The expression of these
A
E
H I J
F
G
B C D
Figure 3.
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fragments in embryos was monitored by Western blotting
(Fig EV1J).
We also asked whether PAWS1 activates Wnt signalling in
mammalian cells. To this end, we overexpressed PAWS1 in
HEK293 human kidney cells and in U2OS osteosarcoma cells
before stimulating with control or Wnt3A-conditioned medium and
measuring Wnt-dependent TOPFlash luciferase reporter activity
[23]. In both cell lines, Wnt3A conditioned medium induced
TOPFlash luciferase activity when compared with the control
(Fig 3J). Overexpression of PAWS1 substantially enhanced activity
under both conditions, as did inhibition of GSK-3 activity by treat-
ment with LiCl (Fig 3J). Consistent with these observations, Wnt-
induced TOPFlash luciferase activity in PAWS1/ U2OS cells was
significantly less than in wild-type controls (Fig 4A), as was Wnt-
induced activation of its endogenous target genes AXIN2 and
CYCLIN D1 (Fig 4B).
To ask where within the Wnt signalling pathway PAWS1 is likely
to act, we employed epistasis experiments in animal caps. The
induction of Siamois, a direct Wnt target, in naı¨ve animal caps
injected with xWnt8 mRNA is inhibited following injection of a
dominant negative Wnt receptor Lrp6 m5 (Fig 4C). In contrast,
Lrp6 m5 was unable to inhibit Siamois expression in caps injected
with xPAWS1 mRNA, suggesting that PAWS1 acts downstream of
the Wnt receptor (Fig 4D). Overexpression of C-cadherin in animal
caps can inhibit Wnt signalling by acting as a molecular sink and
sequestering stabilised b-catenin to the cell surface, thereby inhibit-
ing nuclear accumulation of b-catenin [24]. Therefore, agonists that
promote Wnt signalling downstream of b-catenin are unaffected by
C-cadherin overexpression. PAWS1-dependent induction of Siamois
expression was blocked by C-cadherin (Fig 4D), suggesting that
PAWS1-mediated activation of Wnt signalling requires b-catenin.
Ubiquitin-mediated degradation of b-catenin is regulated through
the destruction complex, in which CK1, GSK-3 and Axin1 play key
roles [25–27]. Overexpression of Axin1 in animal caps completely
blocked xPAWS1-induced Siamois expression, while overexpression
of GSK-3 did so partially (Fig 4D). Consistent with this notion, in
PAWS1/ U2OS cells, inhibition of GSK-3 with the selective inhi-
bitor CHIR99021 had no effect on Wnt-reporter activity (Fig 4E),
while in WT cells inhibition of GSK-3, which stabilises b-catenin
[28], yielded maximal induction of Wnt-reporter activity, even in
the absence of Wnt stimulus. Together, these results suggest that
PAWS1 functions in Wnt signalling at the level of the destruction
complex or subsequent to it.
PAWS1 interacts with CK1a
To understand the mechanisms by which PAWS1 stimulates canoni-
cal Wnt signalling at the level of the destruction complex, we
employed a proteomic approach to identify interactors of endoge-
nous PAWS1. For this, we first generated U2OS cells in which we
introduced a GFP tag at the C-terminus of the endogenous PAWS1
gene on both alleles (Fig EV1K and L). Using these PAWS1GFP/GFP-
knock-in cells, we performed anti-GFP IPs to pull down endogenous
PAWS1-GFP and its interacting partners (Fig 5A). Casein kinase 1a
(CK1a) isoform was identified as the major interactor of PAWS1 by
mass spectrometry (Figs 5A and EV1M and N). CK1a plays a central
role in Wnt signalling and phosphorylates many components of the
pathway, including b-catenin at the destruction complex [29,30]. By
Western blotting, endogenous CK1a was detected in anti-GFP IPs
from PAWS1GFP/GFP knock-in cells but not from PAWS1/ U2OS
cells (Fig 5B). Similarly, endogenous PAWS1 was detected in
endogenous CK1a IPs from wild-type but not PAWS1/ U2OS cells
(Fig 5C). Stimulating cells with Wnt3A did not affect the ability of
PAWS1 to interact with endogenous CK1a (Fig EV1O), suggesting
that the interaction between PAWS1 and CK1a does not depend on
Wnt stimulation.
◀ Figure 3. PAWS1 activates Wnt signalling.A xPAWS1 stabilises exogenous b-catenin in whole embryos. Xenopus embryos were injected into the animal pole at the one-cell stage with mRNAs encoding either
50 pg of b-cat_GFP or with 50 pg of b-cat_GFP and 250 pg xPAWS1_mCherryHA mRNAs. At stage 10, embryo extracts were immunoblotted with the indicated
antibodies. Top panel: anti-HA and anti-GFP antibodies; middle panel: anti-active b-catenin (single white asterisk is active b-catenin_GFP; double white asterisk is
endogenous active b-catenin) and anti-a-tubulin antibodies; bottom panel: anti-GFP and anti-a-tubulin antibodies.
B xPAWS1 stabilises endogenous b-catenin in naïve animal caps. Embryos were injected at the one-cell stage with 250 pg of xPAWS1_mCherryHA mRNA. At stage
8.5, animal caps were collected from injected and uninjected embryos and cultured until control embryos reached stage 10. Extracts were immunoblotted with the
indicated antibodies. Top panel: anti-active b-catenin and anti-a-tubulin antibodies; bottom panel: anti-HA, anti-b-catenin and anti-a-tubulin antibodies.
C, D Quantification of (A and B), respectively. In (C), b-catenin_GPF or active b-catenin_GFP bands were normalised to a-tubulin and then expressed as a fold change
relative to the expression of b-catenin_GFP and active b-catenin_GFP respectively from embryos injected with b-catenin_GFP alone. In (D), endogenous b-catenin
and active b-catenin were normalised to a-tubulin and then expressed as a fold change relative to the expression of b-catenin and active b-catenin (respectively)
from uninjected cells.
E Nuclear translocation of b-catenin_GFP. Dissociated animal cap cells injected with either 50 pg of b-catenin_GFP or with 50 pg b-catenin_GFP and 250 pg
xPAWS1_mCherryHA mRNAs were plated on coverslips and imaged by confocal microscopy. Only b-catenin_GFP cells co-injected with xPAWS1_mCherryHA mRNA
accumulated robust levels of b-catenin in the nucleus. Scale bars are 20 lm.
F xPAWS1 induces expression of Siamois and Chordin transcripts in animal caps. Embryos were injected at the one-cell stage with 250 pg of MT_xPAWS1 mRNA, and
then at stage 8.5, animal caps were collected from injected and uninjected embryos and assessed for Chordin and Siamois expression by qPCR (n = 3; error bars
represent  SD, **P = 0.001, ***P = 0.0001; ordinary one-way ANOVA with multiple comparisons, uninjected as control column).
G–I The DUF1669 domain (G, in red) is necessary but not sufficient to induce a secondary axis (H) and activate Siamois expression (I) while the BMPR1 phosphorylation
sites S610, S613 and S614 (yellow) are dispensable (n = 3; error bars represent  SD). 250 pg of MT_xPAWS1 mRNAs encoding N- and C-terminal truncation
fragments were injected into one ventral blastomere at the four-cell stage. Axis induction was assessed at stage 28. In (I), embryos were injected at the one-cell
stage with 250 pg of MT_xPAWS1 mRNAs encoding N- and C-terminal mutants, and then at stage 8.5, animal caps were collected and assessed for Siamois
expression by qPCR.
J HEK293 and U2OS cells were transfected with PAWS1 cDNA, or empty vector as a control and TOPFlash luciferase activity was measured after treatment with
either conditioned medium (L-CM), Wnt3A-conditioned medium (L3-CM) or 20 mM LiCl for 12 h. Data are normalised to Renilla internal control (n = 4; error bars
represent  SEM).
Source data are available online for this figure.
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To map the interaction sites between PAWS1 and CK1a, we co-
expressed truncated fragments of PAWS1 with CK1a and performed
co-IP interaction assays. From these assays, we determined that the
region spanning residues 165-307 within the DUF1669 domain was
sufficient for mediating CK1a interaction [31]. Within this region,
PAWS1 contains an F296-X-X-X-F300 motif that has been reported to
mediate interaction between CK1a and NFAT1, PER1 and PER2
proteins [32]. In order to determine whether the F296-X-X-X-F300
motif within PAWS1 indeed mediates its association with CK1a, we
generated FLAG-PAWS1 F296A, F300A or F296A/F300A mutants
and overexpressed them in U2OS cells. Endogenous CK1a was
detected in anti-FLAG IPs from wild-type FLAG-PAWS1 and FLAG-
PAWS1F300A but not from FLAG-PAWS1F296A and FLAG-
PAWS1F296A/F300A (Fig 5D), suggesting F296 in PAWS1 contributed
to the association with CK1a. For PER1/2, it has been shown that
both Phe residues within the F-X-X-X-F motif are essential for inter-
action with CK1a, as mutating either contributed to the loss of inter-
action with CK1 [32]. However, for PAWS1, the fact that
PAWS1F300A was still able to interact with CK1a suggested that the
mode of interaction with CK1a is mediated through additional
mechanisms. We tested further point mutations on conserved resi-
dues along the aa165-aa307 stretch of PAWS1 for their ability to
abolish the interaction with CK1a and found that mutating the
conserved D262 to A (PAWS1D262A) also abolished the association
with CK1a (Fig 5D). We tested the ability of GFP control,
PAWS1WT, PAWS1F296A or PAWS1D262A to interact with endogenous
CK1a when these were stably restored in PAWS1/ cells. IPs of
endogenous CK1a pulled down PAWS1 only from PAWS1WT rescue
cells but not others (Fig 5E).
To test whether, and if so where, PAWS1 and CK1a co-localise in
cells, we restored the expression of PAWS1WT or PAWS1F296A in
PAWS1/ U2OS cells. By immunofluorescence, we observed that
PAWS1WT and CK1a displayed overlapping cytoplasmic staining,
while PAWS1F296A and CK1a displayed non-overlapping cytoplasmic
staining and, as expected, no PAWS1 was detected in PAWS1/
cells (Fig 5F). Interestingly, the CK1a staining in PAWS1/ and
PAWS1F296A rescue cells was much weaker than in PAWS1WT
rescue cells (Fig 5F), suggesting that PAWS1 might play a role in
cellular CK1a protein levels.
PAWS1 regulates cellular CK1a protein levels
The robust association and co-localisation of PAWS1 with CK1a
has several implications for the role of PAWS1 in the Wnt signal-
ling pathway. These include (i) PAWS1 is a substrate of CK1a; (ii)
PAWS1 controls CK1a activity; and (iii) PAWS1 controls CK1a
A B
C D E
Figure 4. Loss of PAWS1 inhibits Wnt signalling at the level of the destruction complex.
A Relative TOPFlash luciferase activity of PAWS1WT and PAWS1/ U2OS cells after treatment with conditioned media (L-CM) or Wnt3A-conditioned media (L3-CM)
(n = 3; error bars represent  SEM).
B Wnt3A-induced activation of the target genes AXIN2 and CYCLIN D1 was examined by qPCR at the indicated time points in PAWS1WT and PAWS1/ U2OS cells.
Transcript expression data are represented as fold induction over unstimulated control and are internally normalised to b-actin control. Error bars
represent  SEM (***P < 0.0001; two-way ANOVA with multiple comparisons; n = 3).
C, D Epistasis analysis of xPAWS1 in the canonical Wnt pathway. Xenopus embryos were injected at the one-cell stage with the indicated mRNAs, and then at stage 10,
animal caps were assessed by qPCR for the expression of Siamois. xPAWS1 acts downstream of the Wnt receptor LRP6 (C) at the level of the destruction complex
(D) (n = 3 error bars represent  SD).
E Relative TOPFlash luciferase activity of PAWS1WT and PAWS1/ U2OS cells after treatment with either conditioned medium (L-CM), Wnt3A-conditioned medium
(L3-CM) or 5 lM of the GSK3 inhibitor CHIR99021 for 6 h. Data are normalised to Renilla-luciferase internal control (n = 4; error bars represent  SEM).
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stability and/or levels in cells. We sought to test these possibili-
ties.
In vitro, CK1a phosphorylated PAWS1 and we mapped the CK1a
phosphorylation site on PAWS1 to Ser614 using Edman sequencing
and mass spectrometry (Fig EV2A–C). Consistent with this, CK1a
was no longer able to phosphorylate PAWS1S614A mutant
(Fig EV2D). However, bearing in mind that the PAWS1(1-583) frag-
ment, which lacks Ser614, was still able to cause axis duplication
and activate Wnt signalling in Xenopus embryos (Fig 3G–I), the
phosphorylation of PAWS1 at Ser614 by CK1a is unlikely to explain
its role in Wnt signalling. Furthermore, the PAWS1S610A/S614A
mutant was still able to induce axis duplication (Fig EV2E). As yet,
we have not determined whether endogenous PAWS1 is phosphory-
lated at Ser614 by CK1a in vivo.
We also tested the ability of PAWS1 to influence CK1a activity
against a peptide substrate (CK1tide) [33]. First, we detected robust
CK1a kinase activity in endogenous PAWS1 IPs from wild-type but
not PAWS1/ U2OS cell extracts (Fig 6A). The detection by
Western blotting of endogenous CK1a in PAWS1 IPs from wild-type
but not PAWS1/ cell extracts correlated with the observed in vitro
kinase activities against CK1tide (Fig 6A). These observations
suggest that the association of PAWS1 with CK1a does not inhibit
intrinsic CK1a kinase activity. Next, we tested whether PAWS1
potentiated the kinase activity of recombinant CK1a through associ-
ation. Human recombinant CK1a expressed in E. coli displayed
in vitro kinase activity against CK1tide, while the catalytically inac-
tive (KD; D136N) mutant of CK1a did not (Fig 6B). The addition of
recombinant human PAWS1WT or the CK1-interaction-deficient
A
B D
F
C E
Figure 5. PAWS1 interacts with CK1 at the endogenous level.
A GFP pull downs from U2OS PAWS1/ and PAWS1GFP/GFP cells were resolved by SDS–PAGE, and the gel was stained with Coomassie. Each lane was cut into six pieces,
which were subsequently processed for protein identification by mass spectrometry.
B GFP pull downs from U2OS PAWS1/ and PAWS1GFP/GFP cells were resolved by SDS–PAGE and analysed by Western blotting using the indicated antibodies.
C Anti-CK1a IPs from U2OS PAWS1WT and PAWS1/ cells were resolved by SDS–PAGE and analysed by Western blotting using the indicated antibodies.
D U2OS cells were transiently transfected with cDNA encoding FLAG-tagged PAWS1WT, PAWS1F296A, PAWS1F300A, PAWS1F296A/F300A, PAWS1D262A and FLAG-empty vector.
Anti-FLAG IPs were immunoblotted with the indicated antibodies.
E Anti-CK1a IPs and IgG-IPs from U2OS PAWS1WT, GFP, PAWS1F296A and PAWS1D262A rescue cells were resolved by SDS–PAGE and analysed by Western blotting using
the indicated antibodies.
F PAWS1 co-localises with CK1a in U2OS cells. PAWS1/ cells in which PAWS1WT or PAWS1F296A expression was restored were fixed for immunofluorescence using
antibodies against PAWS1 and CK1a. Scale bar is 20 lm. Images from one field of view representative of three biological replicates are included.
Source data are available online for this figure.
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PAWS1F296A mutant to the kinase reaction did not significantly
affect the ability of CK1a to phosphorylate CK1tide (Fig 6B). Collec-
tively, these data suggest that PAWS1 is unlikely to directly regulate
the intrinsic CK1a kinase activity.
Strikingly, when we analysed the levels of CK1a protein in
extracts from wild-type and PAWS1/ U2OS cells, we observed
decreased CK1a protein levels in PAWS1/ cells compared to the
WT controls (Fig 6C). When we rescued PAWS1WT in PAWS1/
cells, we noticed a remarkable increase in the endogenous CK1a
protein levels compared to the re-introduction of GFP control
(Fig 6C). Interestingly, the re-introduction of the CK1a-binding-
deficient mutants PAWS1F296A and PAWS1F296A/F300A did not
result in any increased CK1a protein levels, while the PAWS1F300A
mutant, which interacts with CK1a, resulted in increased CK1a
protein levels similar to PAWS1WT rescue (Fig 6C), suggesting that
the binding of PAWS1 to CK1a regulates CK1a protein levels in
cells. The reduction in levels of CK1a protein in PAWS1/ U2OS
cells compared to the WT controls could not be rescued by either
the proteasomal inhibitor Bortezomib or the lysosomal inhibitor
Bafilomycin A1 (Fig EV3A and B). Similarly, the mRNA levels of
CK1a were comparable in PAWS1WT, PAWS1/ and PAWS1F296A
rescue cells (Fig EV3E), suggesting that the PAWS1 regulation of
CK1a protein levels is not through its transcriptional regulation.
In U2OS cells in which we transiently depleted endogenous CK1a
protein with siRNAs, we observed a concomitant reduction in
endogenous PAWS1 protein levels (Fig 6D), suggesting a recipro-
cal effect of PAWS1 and CK1a on controlling cellular protein
levels.
A
B
E
C D
Figure 6. PAWS1 does not affect CK1a activity but affects the protein levels of CK1a in cells.
A Endogenous PAWS1 was immunoprecipitated from wild-type and PAWS1/ U2OS cells (n = 3), and the associated CK1a kinase activity was measured following a
kinase assay using c32P-ATP and the CK1tide peptide substrate. A third of the PAWS1 IP samples were resolved by SDS–PAGE and immunoblotted with the indicated
antibodies (bottom panel) (n = 3, error bars represent  SEM).
B In vitro wild-type (WT) or catalytically inactive (KD) CK1a kinase assay using CK1tide as a substrate in the presence or absence of recombinant PAWS1WT or
PAWS1F296A (n = 3; error bars represent  SEM; one way ANOVA with multiple comparisons, n.s.: no statistical significance).
C Cell extracts from U2OS wild-type, PAWS1/ and PAWS1/ cells in which PAWS1, GFP control, PAWS1F296A, PAWS1F300A, PAWS1F296A/F300A or PAWS1D262A was
restored, were resolved by SDS–PAGE and immunoblotted with the indicated antibodies.
D CK1a expression was silenced in U2OS cells with indicated amounts of siRNA using two different transfection reagents (RNAi-Max or TransFectin) and PAWS1 protein
levels monitored by Western blotting.
E Expression of PAWS1 and CK1a protein in the indicated cell lines was monitored by Western blotting. The protein levels of CK1a mirror the levels of PAWS1 in the
majority of the cancer cell lines tested.
Source data are available online for this figure.
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Prompted by these observations, we examined the potential
correlation in expression of PAWS1 and CK1a proteins in a number
of mammalian cell lines. We observed that PAWS1 protein expres-
sion was absent in many human cancer cells, including SK-ES
(bone), MCF-7 (breast), SK-N-MC (brain), and PC3 (prostate) cells
while robust expression was observed in HCT116 (colorectal),
HEPG2 (liver), PNTA1 (prostate) and HeLa (cervical) cells. Strik-
ingly, the expression levels of PAWS1 in these cells correlated with
the levels of CK1a protein (Figs 6E and EV3C). Cells that lacked
PAWS1 protein expression generally correlated with no detectable or
low levels of CK1a protein, whereas cells that had relatively higher
levels of PAWS1 also expressed relatively higher levels of CK1a
(Figs 6E and EV3C). No correlation in expression was evident
between PAWS1 and CK1e, which does not interact with PAWS1
(Figs 6E and EV3D). In both PC3 and PAWS1/ U2OS cells, which
lack endogenous PAWS1, the restoration of WT PAWS1 increased
the protein levels of endogenous CK1a but not CK1e (Fig 6E) [31]. In
order to test whether the correlation in PAWS1 and CK1a protein
levels was due to a similar correlation in mRNA expression, we
assessed the PAWS1 and CK1a mRNA levels in six of these mamma-
lian cell lines. No discernible correlation was observed with the
expression of PAWS1 and CK1a mRNAs (Fig EV3F–H), indicating
that the correlation between PAWS1 and CK1a protein levels occurs
post-transcriptionally.
Interaction between PAWS1 and CK1a is essential for PAWS1-
dependent axis duplication and the activation of Wnt signalling
Armed with the knowledge that PAWS1 associates and co-localises
with CK1a, we asked whether the association between PAWS1 and
CK1a was essential for PAWS1-dependent activation of Wnt signalling
in Xenopus embryos and in U2OS cells. PAWS1-induced axis duplica-
tion in Xenopus embryos was scored following microinjection with
wild-type PAWS1, three separate CK1a-interaction-deficient PAWS1
mutants, PAWS1D262A, PAWS1F296A and PAWS1F296A/F300A as well as
PAWS1F300A mutant that interacts with CK1a (Fig 7A). Both PAWS1WT
and the PAWS1F300A mutant induced partial or complete axis duplica-
tion in ~80% of embryos. In contrast, PAWS1D262A, PAWS1F296A and
PAWS1F296A/F300A failed to induce secondary axes in the embryos
(Fig 7A). These results demonstrate that the interaction between
PAWS1 and CK1a is essential for PAWS1-mediated axis duplication in
Xenopus embryos. To explore whether the induction of the Wnt-
reporter activity in U2OS cells also required interaction between
PAWS1 and CK1a, we assessed the Wnt-reporter activity in wild-type,
PAWS1/ and PAWS1/ cells rescued with either PAWS1WT or the
PAWS1F296A mutant. The treatment of wild-type cells with Wnt3A
substantially enhanced the luciferase reporter activity over unstimu-
lated controls, while in PAWS1/ cells it did not (Fig 7B). In
PAWS1/ cells rescued with wild-type PAWS1, the Wnt3A-induced
luciferase reporter activity was restored. In contrast, it was not restored
in PAWS1/ cells rescued with the PAWS1F296A mutant (Fig 7B),
suggesting that PAWS1 activation of Wnt signalling necessitates
PAWS1: CK1a interaction.
The role of PAWS1:CK1a complex in Wnt signalling
In the absence of Wnt ligands, CK1a has been reported to phosphory-
late b-catenin on Ser45 [34,35], which triggers a sequential
phosphorylation by GSK-3 on Thr41, Ser37 and Ser33 [28], thereby
allowing recruitment of the E3 ubiquitin ligase b-TrCP to b-catenin
for its ubiquitin-mediated proteasomal degradation [26]. Paradoxi-
cally, overexpression of CK1a has been reported to stimulate Wnt
signalling [36], and indeed, human CK1a can also induce a
secondary axis in a dose-dependent manner in Xenopus embryos
(Fig 7C). However, when co-expressed with PAWS1, the axis induc-
tion was blocked (Fig 7D). A possible explanation is that PAWS1
inhibits CK1a activity; hence, the overexpression of CK1a counters
the PAWS1 effects on axis duplication. However, we have shown
earlier that PAWS1 IPs from WT but not PAWS1/ U2OS cells
display CK1a catalytic activity and recombinant PAWS1 does not
impair CK1a activity in vitro (Fig 6A and B). Therefore, these obser-
vations suggest that overexpression of either PAWS1 or CK1a alone
in embryos potentially disrupts the endogenous PAWS1:CK1a
complex homeostasis, resulting in the interference with Wnt signal-
ling that results in the axis phenotypes observed. In contrast, when
these are co-expressed, this interference on the endogenous PAWS1:
CK1a complexes is minimised, so the phenotypes are normal. If this
were the case, then one would expect similar outcomes using a
catalytically inactive mutant of CK1a (Fig 7E), which we have shown
interacts with PAWS1 with similar affinity to the wild-type CK1a
(Fig 7F). Indeed, co-expression of PAWS1 and the catalytically inac-
tive CK1a mutant in Xenopus embryos also resulted in completely
normal embryos (Fig 7E). In similar assays, we also tested the ability
of CK1d and CK1e, which do not interact with PAWS1 [31], to inhibit
PAWS1-dependent axis duplication phenotype in Xenopus embryos.
Unlike CK1a, CK1d and CK1e or the catalytically inactive CK1e were
unable to block the axis duplication phenotype caused by PAWS1
(Fig 7E). Like CK1a, CK1d and CK1e isoforms on their own also
induced axis duplication in Xenopus embryos (Fig 7E), suggesting
PAWS1-independent roles in Wnt signalling. Interestingly, catalyti-
cally inactive CK1a and CK1e on their own did not induce axis dupli-
cation, suggesting that the catalytic activity is critical to their impact
on Wnt signalling. Together, our findings suggest that critical regula-
tion of endogenous PAWS1:CK1a complex is vital in driving Wnt
signalling through axis specification during development and subtle
imbalances can interfere with normal development. Not surprisingly,
this feature is shared with the non-canonical Wnt/planar cell polarity
pathway in which slight perturbations lead to defects in developmen-
tal events such as convergent extension and ciliogenesis [37].
Since PAWS1 appears to exist predominantly in a PAWS1:CK1a
complex (Fig 5), we asked whether PAWS1:CK1a also regulated
other CK1a-dependent pathways. One potential target of PAWS1:
CK1a is the transcription factor NFAT, which has been reported to
promote ventral cell fates in the Xenopus embryo [38]. Nuclear
localisation of NFAT is regulated by CK1a via a SSR-1 motif in the
N-terminus, in which phosphorylation of the motif by CK1 promotes
NFAT1 nuclear export, while its dephosphorylation by calcineurin
induces nuclear import. Phospho-deficient SSR-1 motif mutants of
NFAT1 accumulate in the nucleus [32], as does NFAT in cells
treated with a CK1 inhibitor [32], and when overexpressed in Xeno-
pus ventralise embryos [38]. In dissociated animal cap cells express-
ing a NFAT_GFP reporter construct, NFAT_GFP accumulated
predominantly in the cytoplasm (Fig EV4A–C). However, unlike
cells expressing the catalytically inactive CK1a (KD), in which NFAT
was distributed in the both the cytoplasm and the nucleus
(Fig EV4C), we found that xPAWS1 expression had no effect on the
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nuclear localisation of the reporter (Fig EV4A–C), nor did it affect
nuclear localisation of NFAT_GFP following Ca2+ ionophore treat-
ment (Fig EV4A–C) where no cytotoxicity was detected. These data
suggest that, in contrast to the Wnt pathway, the regulation of
nuclear localisation of NFAT is insensitive to perturbations of the
PAWS1:CK1a complex.
PAWS1 does not interact robustly with Axin1 and b-catenin
complexes during Wnt signalling
Having earlier established the role of PAWS1 in Wnt signalling at or
downstream of the destruction complex, we sought to explore the
composition of the destruction complex in the absence of PAWS1.
In order to dissect any changes in the make-up of the destruction
complex, we immunoprecipitated CK1a, Axin1 and b-catenin from
unstimulated and Wnt3A (3 h)-stimulated WT and PAWS1/
U2OS cells and analysed some of the known components of the
destruction complex. In endogenous CK1a IPs from both WT and
PAWS1/ cells, Axin1, GSK-3a/b and b-catenin were not detect-
able, regardless of Wnt3A stimulation, while as expected PAWS1
was identified in CK1a IPs from WT cells but not PAWS1/ cells
(Fig 8). In Axin1 IPs, GSK-3a/b were detected robustly, while very
low levels of b-catenin were also detected, although neither Wnt3A
treatment nor the PAWS1-status had any effect on these Axin1
complexes (Fig 8). Similarly, in b-catenin IPs, we were able to
detect low levels of GSK-3b, as well as CK1d and CK1e but not CK1a
(Fig 8), suggesting that CK1d and CK1e, rather than CK1a, may be
essential in mediating b-catenin phosphorylation at Ser45. CK1a IPs
A D
E
F
B
C
Figure 7. PAWS1 association with CK1a is essential for induction of Wnt signalling.
A PAWS1F296A, PAWS1F296A/F300A and PAWS1D262A mutants that do not interact with CK1a fail to induce a secondary axis in Xenopus embryos.
B Relative TOPFlash luciferase activity of U2OS WT, PAWS1/, PAWS1WT and PAWS1F296A rescue cells after treatment with control-conditioned media (L-CM), Wnt3A-
conditioned media (L3-CM) (n = 3; error bars represent  SEM).
C Human CK1a induces a secondary axis in Xenopus embryos in a dose-dependent manner.
D Co-expression of PAWS1 and CK1a mRNAs do not induce secondary axis.
E Effect of CK1 isoforms on PAWS1-dependent axis-inducing activity. 250 pg of xPAWS1 and 300 pg of the indicated CK1 isoform mRNAs were injected into one ventral
blastomere at the four-cell stage. Axis induction was assessed at stage 28.
F PAWS1 interacts with kinase-dead CK1a in U2OS cells. U2OS cells were co-transfected with HA-CK1a (WT or KD) and FLAG-PAWS1, and cell extracts were subjected to
FLAG IP, followed by SDS–PAGE and Western blot analysis with the indicated antibodies.
Source data are available online for this figure.
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from cells treated with Wnt3A for shorter times (30 min and 1 h)
did not pull down any significant levels of b-catenin and no dif-
ferences were observed between WT and PAWS1/ U2OS cells
(Fig EV5A). With no significant differences in Axin1, GSK-3a/b and
b-catenin complexes detected in the absence of PAWS1, we under-
took an unbiased proteomic approach to identify interactors of
PAWS1-GFP expressed in U2OS cells under unstimulated and
Wnt3A (3 h)-stimulated conditions (Fig EV5B). However, other
than CK1a and CK1a-like, no major components of either the Wnt
pathway or the destruction complex were identified in the PAWS1-
GFP IPs under both control and Wnt3A-stimulated conditions
(Fig EV5C). While some PAWS1 interactors, such as PLOD1 and
many 14-3-3 proteins, were substantially enriched in Wnt3A-stimu-
lated conditions, albeit with much lower abundance compared to
CK1a and CK1a-like, these still need to be validated further and
their roles in Wnt signalling are not well established (Fig EV5B). As
14-3-3 proteins are binders of phospho-proteins [39], we analysed
all phospho-residues on PAWS1 by mass spectrometry. Interest-
ingly, some phospho-residues on PAWS1, namely Ser127, Ser634 and
Ser726, appeared to be enriched by Wnt3A stimulation (Fig EV5D).
Clearly, these need to be validated at the endogenous level and the
functional relevance of these is unclear.
PAWS1 impacts the nuclear translocation of b-catenin
downstream of the destruction complex
Next, we assessed the effect of PAWS1-loss on the post-translational
regulation of b-catenin. To this end, we analysed b-catenin phos-
phorylation on known CK1 (Ser45) and GSK3 (Thr41, Ser37 and
Ser33) phospho-sites and its subcellular distribution. In WT U2OS
cells, Wnt3A stimulation resulted in acute reduction in levels of
both phospho-Ser45 and phospho-Thr41, -Ser37 and -Ser33 residues
within 30 min, while the levels then recovered in a time-dependent
manner (Fig 9A). This is in agreement with the accumulation of
active non-phosphorylated (Thr41, Ser37 and Ser33) form of either
endogenous b-catenin or ectopic b-catenin-GFP observed in Xenopus
animal caps injected with xPAWS1 (Fig 3A–D). No significant dif-
ferences in total endogenous b-catenin levels were observed over
the Wnt3A stimulation time course in either cell type, suggesting
that in U2OS cells, only a small pool of total b-catenin might be
regulated by Wnt3A treatment (Fig 9A). Interestingly, under unstim-
ulated basal conditions in which cells were grown in DMEM
containing 10% serum, slightly higher levels of both CK1a (Ser45)
and GSK3 (Thr41, Ser37 and Ser33) phospho-sites in b-catenin were
observed in PAWS1/ extracts compared to the wild type (Fig 9A).
No substantial differences between the wild-type and PAWS1/
cells were observed when we analysed the levels of Wnt-induced
phosphorylation of LRP6 at Ser1490 (Fig 9A). We also assessed the
expression of AXIN2 protein, a target of Wnt, in wild-type and
PAWS1/ cells over the course of 16 h of Wnt3A stimulation. Like
Wnt3A-induced AXIN2 mRNA expression earlier (Fig 4B), we
observed that a time course of Wnt3A stimulation induced an
increase in AXIN2 protein levels in wild-type U2OS cells, while this
increase was less pronounced in PAWS1/ cells (Fig 9A). Since the
Wnt3A-induced phospho- and total b-catenin levels in U2OS cell
extracts did not appear to change significantly to account for the
inhibition of Wnt signalling caused by loss of PAWS1, we analysed
the cytoplasmic and nuclear distribution of b-catenin in wild-type,
PAWS1/, and PAWS1WT and PAWS1F296A rescue U2OS cells upon
Wnt stimulation (Fig 9B). We monitored pSer45, pThr41/Ser37/Ser33,
non-phospho Ser45 and Thr41 (so-called a-active b-catenin mono-
clonal antibody [40]) and total b-catenin levels. Compared to wild-
type and PAWS1WT rescue cells, both basal and Wnt-induced levels
of b-catenin-pSer45, b-catenin-pThr41/Ser37/Ser33, active b-catenin
and to some extent total b-catenin in nuclear, but not cytoplasmic,
fractions were markedly lower in PAWS1/ and PAWS1F296A
rescue cells (Fig 9B). This was particularly evident when we anal-
ysed the levels of active b-catenin in each fraction relative to that
present in the cytoplasmic fraction of WT U2OS cells (Fig 9B, lower
panel), suggesting that PAWS1 potentially promotes nuclear accu-
mulation of b-catenin. In WT and PAWS1WT and PAWS1F296A
rescue U2OS cells, PAWS1 was observed in both cytoplasmic and
nuclear fractions, with slight enrichment in cytoplasmic fractions.
However, more CK1a was detected in the nuclear fractions than
cytoplasmic, except that there was less overall CK1a detected in
PAWS1/ and PAWS1F296A rescue cells compared to WT and
PAWS1WT rescue cells (Fig 9B). These observations suggest that
other FAM83 members that also bind CK1a probably account for the
Figure 8. PAWS1 does not appear to affect Axin1 and b-catenin
complexes upon Wnt signalling.
U2OS wild-type (WT) and PAWS1/ (KO) cells were treated with control-
conditioned medium or Wnt3A-conditioned medium, and the extracts (0.5 mg
protein) were subjected to immunoprecipitation using antibodies against the
endogenous CK1a, AXIN1 and b-catenin antibodies or anti-rabbit pre-immune
IgG as a control (10 lg antibodies coupled to 10 ll packed protein-G sepharose
beads). IPs were resolved by SDS–PAGE and immunoblotted with the indicated
antibodies.
Source data are available online for this figure.
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enhanced nuclear pool of CK1a [31]. Because most of the b-catenin
protein is reported to be associated with the plasma membrane
[41,42], we assessed the effect of PAWS1-loss on membrane-asso-
ciated pool of b-catenin. We also found high levels of total b-catenin
in the plasma membrane fractions and quite substantial amounts in
the cytoskeletal fractions, when compared to cytoplasmic and
nuclear fractions (Fig EV5E). However, neither the loss of PAWS1
nor Wnt3A stimulation changed the levels of b-catenin protein in
both the membrane and cytoskeletal fractions (Fig EV5E). Under
these conditions, very low levels of PAWS1 and CK1a were detected
in the membrane and cytoskeletal fractions (Fig EV5E).
Discussion
We have shown previously that PAWS1 modulates a subset of non-
canonical SMAD4-independent genes in the BMP signalling pathway,
yet has no effect on the canonical BMP pathway [1]. Consistent with
this, we find here that PAWS1 does not affect canonical BMP signalling
in either Xenopus embryos or U20S cells. In contrast, we demonstrate
here that PAWS1 plays a significant role in regulating Wnt signalling in
both developing Xenopus embryos and human cells. Furthermore, we
find that the association between PAWS1 with CK1a is necessary to
modulate Wnt signalling. The precise mechanisms for the coordinated
actions of PAWS1 and CK1a in Wnt signalling, and perhaps beyond,
remain to be established but our findings indicate that PAWS1 regu-
lates cellular levels and subcellular localisation of CK1a protein, and
potentially the phosphorylation of CK1a substrates. Collectively, our
findings establish PAWS1 as a novel player in the Wnt signalling path-
way and a critical regulator of CK1a.
It has long been known that CK1 isoforms play crucial roles in the
Wnt/b-catenin signalling [28–30,34,35,43–46]. In fact, early observa-
tions that overexpression of CK1 isoforms in Xenopus embryos
caused axis duplication suggested a positive role for CK1 in Wnt
signalling [47]. However, it has since become evident that CK1
isoforms play both negative and positive roles in the Wnt/b-catenin
signalling [29], and their activities may be regulated in a coordinated
fashion [48]. The precise mechanisms by which CK1 isoforms are
A B
Figure 9. PAWS1 promotes Wnt signalling through increased accumulation of nuclear active b-catenin.
A U2OS wild-type and PAWS1/ cells were exposed to either Wnt3A or control medium for the indicated time points. Cell extracts were subjected to SDS–PAGE
followed by Western blot analysis with the indicated antibodies.
B U2OS wild-type (WT), PAWS1/ (KO), PAWS1WT (+WT) and PAWS1F296A (F/A) rescue cells were exposed to either Wnt3A or control medium for 3 h followed by
separation and preparation of cytoplasmic and nuclear fractions. The extracts were subjected to SDS–PAGE followed by Western blot analysis with the indicated
antibodies. The lower panel represents the fold changes in active b-catenin intensities in each fraction relative to those seen in the cytoplasmic fraction of control WT
U2OS cells. The intensities of the active b-catenin bands in each fraction were quantified by using the ImageJ software.
Source data are available online for this figure.
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regulated to allow them to execute these opposing outcomes in Wnt/
b-catenin signalling remain elusive. From our data, it is evident that
PAWS1 and CK1a coordinate to modulate Wnt signalling but the
influence of CK1d and CK1e on Wnt signalling is not affected by
PAWS1. This suggests that different CK1 isoforms target specific sets
of substrates in cells and are uniquely regulated in driving specific
cellular processes, including Wnt signalling. In this context, our find-
ings that different FAM83 members, of which PAWS1 is a member,
associate and co-localise with different CK1 isoforms suggest that
perhaps coordinated actions of one or more FAM83 members may
define CK1 isoform-specific substrates and actions in the Wnt/b-
catenin signalling and beyond [31].
In the absence of Wnt signalling, it has been reported that
autophosphorylation of the C-terminal domains of CK1d and e inhi-
bits their catalytic activity, which is relieved upon Wnt stimulation
by yet-unidentified phosphatases [49,50]. On the other hand, CK1a
is constitutively active and therefore must be regulated in a different
manner. One attractive model is the “scaffold or proximity effect”
(reviewed in [29,51]). In this model, rather than directly regulating
catalytic activity, scaffold proteins facilitate kinase activity by regu-
lating substrate proximity to the kinase [52]. For example, Axin,
which interacts with GSK3b, enhances b-catenin phosphorylation by
CK1a and GSK3b, without altering CK1a kinase activity [53–56].
Similarly, PAWS1 may act as a scaffold by regulating the access of
CK1a to its substrates. Consistent with this notion, we find that
PAWS1 IPs from cells display CK1a catalytic activity and recombi-
nant PAWS1 has no effect on intrinsic CK1a kinase activity in vitro.
Our observations that while PAWS1 and Axin form robust
complexes with CK1a and GSK3b, respectively, neither appears to
bind b-catenin or other known Wnt pathway components robustly
are consistent with the potential scaffolding roles of PAWS1 and
Axin in facilitating the phosphorylation of CK1a and GSK3b
substrates respectively, as protein kinases often engage with their
substrates only transiently. It is still unclear precisely how PAWS1
acts in concert with CK1a and it remains feasible that PAWS1 regu-
lates CK1a substrate availability in either a positive or negative fash-
ion. From our data, the PAWS1:CK1a complex does not appear to
regulate the phosphorylation of b-catenin at Ser45; however, the
nuclear accumulation of b-catenin appears to require PAWS1:CK1a
complex. We have also shown that all members of the FAM83
family can associate and co-localise with CK1a, while some also
interact with CK1d and CK1e isoforms, suggesting that other
FAM83:CK1 complexes may act redundantly or in a coordinated
fashion to control Wnt/b-catenin signalling [31].
Future work will identify and characterise the PAWS1-dependent
CK1a substrates that may be essential for mediating Wnt signalling,
using phospho-proteomic approaches in wild-type and PAWS1/
cells and address the molecular basis for interaction between
PAWS1 and CK1a. Similarly, investigations are underway to under-
stand how CK1a protein levels are regulated by PAWS1.
Materials and Methods
Plasmids, antibodies and reagents
All constructs were sequence-verified by the DNA Sequencing
Service, University of Dundee (http://www.dnaseq.co.uk). They
included PAWS1-GFP donor (DU48585), sense (DU48793) and anti-
sense (DU48826) gRNAs, pCMV5-FLAG-PAWS1 (DU33274), FLAG-
PAWS1 F296A/F300A (DU28026), FLAG-PAWS1 F296A (DU28024)
and FLAG-PAWS1 F300A (DU28025), pBabe puro PAWS1
(DU33460), pBabe puro FAM83G F296A (DU28044), pBabe puro
FAM83G F300A (DU28045), pBabe puro FAM83G F296A/F300A
(DU28046), pcDNA5-Frt/TO-PAWS1-GFP (DU42816) and pcDNA5-
Frt/TO-GFP (DU41455). For bacterial expression of proteins, PAWS1
wild type and mutants were cloned in pGEXP1 vectors. These
include pGEXP-1 GST-PAWS1-6xHis (DU28293), pGEXP-1 GST-
PAWS1 S614A (DU33321) and pGEXP-1 GST-PAWS1 F296A
(DU28047). These constructs are available to request from the MRC-
PPU reagents webpage (http://mrcppureagents.dundee.ac.uk) and
the unique identifier (DU) numbers indicated above provide direct
links to the cloning strategies and sequence details.
Antibodies included PAWS1 (DU33022), SMAD1 (DU19291),
CK1a (Bethyl Laboratories #Α301-991A-M), CK1e (CST #12448), HA
(Sigma HA-7 #H3663), FLAG-HRP (Sigma #A8592), GFP (Abcam,
#ab6556), Myc tag (Sigma 9E10 #M5546), a-tubulin (ThermoScien-
tific #MA1-80189, Sigma #T5168), AXIN2 (CST #76G6), AXIN1 (CST
#2074), b-catenin (CST #D10A8; Santa Cruz Biotechnology #H-102),
GSK3-a/b (Santa Cruz #sc-7291), GSK3b (CST #9315S), SLC5A10
(Abcam, #ab167156), active b-catenin (Millipore #05-665, CST
D13A1 #8814), LRP6 (CST #C47E12), GAPDH (CST #D16H11),
Lamin A/C (CST #2032) and HA-HRP (Roche 2013819001). All phos-
pho-antibodies were purchased from Cell Signaling Technologies.
Xenopus Addgene constructs pCS2AxinMT (#16298) pCS2 GSK3b
9SA (#16333) were a kind gift from Peter Klein, Xi He kindly
provided pCS2LRP6-m5 (#27283); Randall Moon pCS2 b-catenin-
GFP (#16839), Super 8× TOPFlash (#12456), Super 8× FOPFlash
(#12457), xCK1e D128N (#16726); William Hahn and David Root
CK1a (#23355); and Barry Gumbiner pCS2C-cadherin (#17023). The
ORFs of Xenopus FAM83G (xPAWS1; Image Clone MGC:98851
Source Bioscience), CK1d (image clone #5571715 Source
Bioscience), CK1e (Image Clone #6316339, Source Bioscience) were
cloned into pENTR-D-TOPO (Invitrogen) vector and then transferred
into pCS2_N-MT, pCS2_N-HA, pCS2_C-HA, pCS2_c-mCherryHA
destination vectors using LR clonase (Invitrogen). The catalytically
inactive forms of CK1a (CK1a KD, D136N) were generated by site-
directed mutagenesis. pCS2nuc b-gal and pCS2 H2B_RFP were kind
gifts from Anna Philpott (University of Cambridge) and Sean Mega-
son (Harvard University), respectively.
Recombinant TGFb1 and BMP2 were purchased from R&D
Systems. Bortezomib was from LC Laboratories. Doxycycline was
from Sigma and CHIR99021 from Axon. Recombinant kinases were
generated by the MRC-PPU protein expression team. These include
CK1a (DU329) and CK1a(D136N) (DU28371).
Xenopus maintenance and manipulations
Regulations for the use of Xenopus laevis, as outlined in the Animals
Scientific Procedures Act (ASPA) and implemented by the Home
Office in the UK, were followed. Xenopus laevis embryos were
obtained by in vitro fertilisation and staged according to Nieuwkoop
and Faber (1975). Embryos were injected with capped RNA synthe-
sised using SP6 mMessage mMachine kit (Invitrogen). Animal caps
assays were as described [57]. Dissociated animal caps were plated
onto l-Slide 8-well glass bottom chamber slides (#80827, Ibidi) or
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12-well lChamber slides (#81201) coated with 3 lg/ml recombinant
human E-cadherin protein (#8505-EC-050; R&D Systems) in 0.7×
Marc’s Modified Ringers (MMR; 0.1 M NaCl, 2 mM KCl, 1 mM
MgSO4, 2 mM CaCl2, 5 mM HEPES pH 7.8, 0.1 mM EDTA).
In situ hybridisation
Whole-mount in situ hybridisation was performed as described
[58], except the triethanolamine and acetic anhydride treatments
were omitted. b-Gal staining was developed using Salmon Gal
(Apollo Scientific #BIMB1026), as an alternative chromogenic
substrate, which produces a light pink colour. Probes were made
using DIG labelling mix (Roche, #11277037910), and developed
using BCIP (Roche, #11383221001), and NBT (Roche,
#11383213001). Images of stained embryos were captured using a
Leica DFC310FX camera attached to a Leica M165FC microscope
controlled by LAS V4.9 software.
Immunofluorescence
Dissociated animal cap cells injected with b-catenin_GFP and/or
xPAWS1_mCherry mRNAs were imaged live with a Zeiss LSM710
confocal microscope controlled by ZEN Black 2012 software. Post-
acquisition analysis was performed using ZEN Black, Zen Blue 2012
and ImageJ software packages.
For the analysis of SMAD signalling, dissociated animal cap cells
were fixed in MEMFA (0.1 M MOPS pH 7.4, 2 mM EGTA, 1 mM
MgSO4, 3.7% formaldehyde) for 10 min at room temperature and
then washed 3 × 5 min in PBS. Cells were permeabilised with 0.5%
Triton X-100 for 5 min followed by 3 × 5 min washes with PBS and
then blocked in blocking buffer (PBS, 0.1% Tween-20, 1% BSA,
10% goat serum) for 1 h at room temperature. Primary (anti-P-
Smad1, CST #9511) and secondary (anti-rabbit Alexa568, Invitrogen
#A11031) were used at 1:1,000 in blocking buffer, each for 1 h, and
then washed 3 × 5 min with PBS-T. Cells were mounted using
Prolong Gold Antifade Mountant with DAPI (ThermoFisher,
#P36935). Images were captured on Zeiss LSM710 confocal micro-
scope as described above.
For PAWS1 and CK1a IF, cells were fixed with 4% paraformalde-
hyde in PBS for 10 min, and permeabilised with 0.5% Triton X-100
in PBS for 5 min. Coverslips were incubated in blocking buffer (3%
BSA, 0.1% Triton X-100 in PBS) for 30 min, followed by anti-
PAWS1 (1:250, Abcam, ab121750) and anti-CK1a (1:100, Santa
Cruz, sc6477) antibodies in blocking buffer for 1 h. Cells were
washed with 0.1% Triton X-100 in PBS and incubated with Alexa
Fluor-conjugated secondary antibodies (ThermoFisher Scientific)
and DAPI (1 lg/ml). Images were captured using a DeltaVision
system (Applied Precision). Z-series were collected at 0.2 lm inter-
vals and deconvolved using SoftWoRx (Applied Precision).
Cell culture
U2OS osteosarcoma cells, HEK293 cells, mouse fibroblast L-cells
that stably overexpress Wnt3A (ATCC, CRL-2647) or L cells (ATCC,
CRL-2648) were grown in Dulbecco’s Modified Eagle’s Medium
(DMEM; Gibco) supplemented with 10% (v/v) FBS (Hyclone),
2 mM L-glutamine, 100 units/ml Penicillin and 100 lg/ml Strepto-
mycin (Lonza). Flp-IN TRex U2OS cells were maintained in growth
media supplemented with 15 lg/ml blasticidin and (100 lg/ml)
zeocin. Cells were grown until confluent at 37°C in a humidified
incubator at 5% CO2. Prior to lysis, cells were stimulated as
described in the figure legends. For transient transfections, cells
were transfected with cDNA plasmids (2.5 lg per 10-cm dish unless
indicated otherwise) using polyethylenimine (PEI) (Polysciences
Inc.) in OptiMem (Gibco) medium as described previously [59].
Preparation of cell extracts
Before being harvested, cells were rinsed in ice-cold PBS and
extracted in lysis buffer containing 50 mM Tris–HCl pH 7.5, 1 mM
EGTA pH 8, 1 mM EDTA pH 8, 1 mM activated Na3VO4, 10 mM Na
b-glycerophosphate, 50 mM NaF, 5 mM Na Pyrophosphate,
270 mM Sucrose, 1% (v/v) Nonidet P-40 and a protease inhibitor
cocktail (1 tablet per 25 ml buffer) (Roche). Cell lysates were clari-
fied by centrifugation at 13,000 × g for 20 min at 4°C. Supernatant
was recovered (cell extract), and protein concentration was deter-
mined in a 96-well format using Bradford protein assay reagent
(Pierce). For nuclear and cytoplasmic extraction, a NE-PER kit from
Thermo Scientific (#78833) was used in accordance with the manu-
facturer’s instructions. For membrane and cytoskeletal protein
extraction, a compartment protein extraction kit from Merck
(#2145) was used according to the manufacturer’s instructions.
Xenopus extracts were prepared by titrating either embryos or
animal caps with 10 ll/embryo or 2 ll/animal cap of embryo lysis
buffer (1% Triton X-100, 150 mM NaCl, 10 mM K-HEPES pH 7.5,
2 mM EDTA, Roche protease inhibitor cocktail). Lipids and yolk
were removed by extracting the lysate with an equal volume of
1,1,2-Trichloro-1,2,2-trifluoroethane (FREON, Sigma Aldrich).
Immunoprecipitation and immunoblotting
0.5–1 mg of total cell lysate protein was incubated with 10 ll beads
(GFP-Trap or anti-FLAG-M2 or 10 lg anti-CK1a antibody conju-
gated to 10 ll Protein G-agarose beads (Abcam)) for 2 h at 4°C on a
rotating platform. IPs were washed twice in lysis buffer supple-
mented with 250 mM NaCl and once in Buffer A (50 mM Tris–HCl
pH 7.5, 0.1 mM EGTA). Immunoprecipitated proteins were dena-
tured in SDS sample buffer supplemented with 1% b-mercap-
toethanol and then subjected to SDS–PAGE. After SDS–PAGE, the
proteins were transferred to PVDF membrane. The membrane was
blocked with 5% non-fat dry milk in TBS-T buffer (50 mM Tris–
HCl, pH 7.5, 0.15 M NaCl and 0.1% Tween-20) for 30 min and then
with primary antibody (1:1,000 in TBS-T with 5% BSA) overnight at
4°C. Blots were incubated for 1 h at room temperature with HRP-
conjugated secondary antibodies (1:5,000 in 5% non-fat dry milk).
Proteins were visualised using the ECL system (GE Healthcare).
Xenopus extracts were denatured in 4× loading buffer (LiCor,
#928-40004) supplemented with 10% v/v b-mercaptoethanol, and
either 1 embryo equivalent, or 10 animal cap equivalents were
loaded per well of a 7.5% mini-Protean TGX gel (Bio-Rad #456-
1025). Following electrophoresis, proteins were transferred using
Trans-Blot Transfer System onto LF PVDF membranes. Blots were
blocked with a 1:1 mixture of TBS and Odyssey Blocking Buffer
(LiCor #92750000) for 1 h at room temperature and then incubated
in primary antibodies diluted 1:1,000 in blocking buffer overnight at
4°C. Blots were washed 3 × 5 min in TBS-T (TBS, 0.1% Tween-20).
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Secondary antibodies were added (goat anti-rabbit and anti-mouse
Abs labelled with either IRDye 680LT or IRDye 800CW) diluted in
TBS-T supplemented with 0.02% SDS for 1 h at room temperature.
Blots were washed 3 × 5 min in TBS-T and then imaged on a LiCor
Odyssey scanner using ImageStudio software (LiCor). The 700- and
800-nm channels were captured simultaneously at the setting of 5,
the l-setting was at 165 lm with the quality setting set at lowest.
Generation of PAWS1/ U2OS rescue cells stably expressing
PAWS1WT or PAWS1 mutants
Retroviral pBabe-puromycin empty vector or vectors encoding
PAWS1WT or indicated PAWS1 mutants (6 lg) were co-transfected
with pCMV5-gag-pol (3.2 lg) and pCMV5-VSV-G (2.8 lg) into a 10-
cm-diameter dish of ~70% confluent HEK293-FT cells. Briefly,
cDNAs were added to 1 ml Opti-MEM medium to which 24 ll of
1 mg/ml PEI (diluted in 25 mM HEPES pH 7.5) was added. Follow-
ing a brief vortexing (10 s) and incubation at room temperature for
20 min, the transfection mix was added dropwise to the HEK293-FT
cells. 16 h post-transfection, fresh medium was added to the cells.
24 h later, the retroviral medium was collected and filtered through
0.45-lm filters. Target PAWS1/ U2OS cells (~60% confluent)
were infected with the optimised titre of the retroviral medium
(1:100) diluted in fresh medium containing 8 lg/ml polybrene
(Sigma) for 4 h. The retroviral infection medium was then replaced
with fresh medium, and 20 h later, the medium was again replaced
with fresh medium containing 2 lg/ml puromycin for selection of
cells which had integrated the rescue constructs. The rescue cells
were analysed by Western blotting as indicated.
Generation of U2OS PAWS1-GFP knock-in cells (PAWS1GFP/GFP)
by CRISPR/Cas9
U2OS cells were transfected with vectors encoding a pair of guide
RNAs (pBABED-Puro-sgRNA1 and pX335-CAS9-D10A-sgRNA2)
targeting the last exon of PAWS1 (1 lg each) and a donor vector
carrying the GFP construct fused to the last 129 amino acids of the
last exon of PAWS1 (3 lg). 24 and 48 h post-transfection, cells were
cultured in medium containing 2 lg/ml puromycin for selection of
transfected cells. Cells were then cultured in normal medium, and
transfection was repeated followed by 2 days of puromycin selec-
tion. GFP-positive cells were then sorted by flow cytometry, and
single GFP-positive cells were plated on individual wells of two 96-
well plates as described previously [60]. Viable clones were
expanded, and integration of GFP at the target locus was verified by
Western blotting and genomic sequencing.
Generation of doxycycline-inducible Flp-IN TRex U2OS
stable cells
Flp-IN TRex U2OS cells grown in 10-cm dishes were transfected with
1 lg pcDNA5-Frt/TO vector encoding PAWS1-GFP or GFP only and
9 lg pOG44 (Invitrogen), diluted in 1 ml OPTIMEM and 20 ll of
1 mg/ml PEI. 24 h post-transfection, cells were cultured in medium
containing 15 lg/ml blasticidin and 50 lg/ml hygromycin B for 2–
3 weeks (by replacing fresh medium every 2 days) until positive
clones were selected, verified and expanded. Protein expression was
induced with 20 ng/ml doxycycline for 16 h prior to lysis.
Mass spectrometry
PAWS1GFP/GFP cells were lysed in DSP lysis buffer (40 mM HEPES
pH 7.4, 120 mM NaCl, 1 mM EDTA pH 8, 10 mM Na-pyropho-
sphate, 50 mM NaF, 1.5 mM activated Na-orthovanadate, 1% (v/v)
Nonidet P-40, protease inhibitor cocktail (1 tablet per 25 ml buffer)
and 2.5 mg/ml DSP. The lysates were left on ice for 30 min, and
cross-linking reactions were quenched by adding 62.5 mM Tris–HCl
pH 7.5. Clarified lysates were filtered through a 0.45-lm filter and
then subjected to immunoprecipitation using 10 ll of GFP-Trap
beads at 4°C overnight. IPs were washed twice in Lysis buffer
supplemented with 500 mM NaCl and once in Buffer A (50 mM
Tris–HCl pH 7.5, 0.1 mM EGTA). IPs were denatured in LDS sample
buffer (Invitrogen) supplemented with 0.1 M DTT, incubated for
1 h at 37°C and then heated for 5 min at 95°C. Samples were filtered
through a Spin-X column by centrifugation, resolved by 4–12%
gradient SDS–PAGE, and stained with colloidal Coomassie blue
overnight. Gels were destained in distilled H2O until background
staining was minimal. Sections of the gel were excised, trypsin
digested, and peptides prepared for HPLC gradient fractionation and
elution into a Thermo ScientificVelos Orbitrap mass spectrometer as
described previously [61,62]. Ion assignments were conducted by in
silico Mascot scoring (www.matrixscience.com), and peptide
protein assignments were reported in Scaffold 4.3 (www.prote
omesoftware.com).
Dual luciferase reporter assays
Cells (2 × 105) were plated in 6-well plates. 24 h later, 500 ng of
Super TOPFlash or Super FOPFlash and 10 ng of Renilla-luciferase
[63] plasmids were co-transfected using PEI and OPTI-MEM. For
transient PAWS1 expression, 500 ng of pBabe PAWS1 (DU33460)
was included to the transfection mix. 24 h later, cells were treated
with L-conditioned medium or L-Wnt3A-conditioned medium or
20 mM LiCl for 16 h, washed twice with PBS and lysed in passive
Lysis buffer (Promega, #E194A). Firefly and Renilla luciferase activi-
ties were measured as described [60,64]. The firefly luciferase
counts were normalised to Renilla luciferase counts, which repre-
sented a measure of transfection efficiency in each sample.
Quantitative PCR and primers
Total RNA was isolated from cells using the QIAGEN RNeasy kit.
Real-time quantitative reverse transcription PCR (qRT–PCR) was
performed using 1 lg of isolated RNA and the SuperScript cDNA kit
(Bio-Rad) according to the manufacturer’s protocol. qRT–PCRs were
performed in triplicate in a 12 ll reaction volume. Each reaction
included 0.5 lM forward primer, 0.5 lM reverse primer, 50% SYBR
green master mix (Bio-Rad), and cDNA equivalent to 1 ng/ll of RNA
in a CFX96 real-time system qRT–PCR machine (Bio-Rad). The data
were normalised to the geometrical mean of the b-actin gene and
analysed as described previously [62]. Primers were designed using
PerlPrimer and purchased from Invitrogen: AXIN2 forward:
TACACTCCTTATTGGGCGATCA; reverse: TTGGCTACTCGTAAA
GTTTTGGT. CYCLIN D1 forward: GCTGCGAAGTGGAAACCATC;
reverse: CCTCCTTCTGCACACATTTGAA. CK1a forward: GAGGC
AGCTATTCCGCATTC; reverse: TGGGGAGAAACAAATGCTGC.
Actin forward: CCAACCGCGAGAAATGACC; reverse: GGAGTCCATC
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ACGATGCCAG. For RT–PCR in Xenopus laevis, total RNA was
extracted from either embryos or animal caps using TRIzol reagent
(Ambion) according to the manufacturer’s instructions. 1 lg of RNA
was used in the cDNA synthesis reaction using random hexamers
and MMLV-RT (Promega). Quantitative PCR was performed using
LightCycler 480 SYBR Green Master I (Roche) using standard run
template conditions on a LightCycler 480 machine (Roche). Primers
used are as follows: Histone H4 forward: CGGGATAACATTCAGGG-
TATCACT; Histone H4 reverse: ATCCATGGCGGTAACTGTCTTCCT;
Siamois forward: AACCACTTTCCACTCTCCCC; Siamois reverse:
AGAAGTCAGTTTGGGTAGGGC; Msx1 forward: GCAGGAACATCAC
ACAGTCC; Msx1 reverse: GGGTGGGCTCATCCTTCT; Vent1
forward: GCATCTCCTTGGCATATTTGG; Vent1 reverse: TTCCCTT
CAGCATGGTTCACC; Vent2 forward: TGAGACTTGGGCACTGTCTG;
Vent2 reverse: CCTCTGTTGAATGGCTTGCT; Chordin forward:
AACTGCCAGGACTGGATGGT; Chordin reverse: GGCAGGATTTAGA
GTTGCTTC. Data were normalised to Histone H4.
In vitro kinase assays and phospho-mapping
25 ll reactions were set up using 200 ng of kinase, 2 lg of substrate
in buffer containing 50 mM Tris pH 7.5, 0.1 mM EGTA, 10 mM
MgAc2, 2 mM DTT and 0.1 mM [
c32P]-ATP (~500 cpm/pmol). Reac-
tions were performed at 30°C for 30 min and stopped by adding
10 ll LDS buffer with 5% b-mercaptoethanol and heating at 95°C for
5 min. Samples were resolved by SDS–PAGE, and gels were stained
with Instant blue (Expedeon) and dried. Radioactivity was analysed
by autoradiography. Kinase assays against substrate peptide
(CK1tide, DSTT EP5630) were performed as described previously
[33].
For phospho-mapping, [c32P]-phosphorylated PAWS1 was
subjected to trypsin digestion and peptides were reconstituted to a
final concentration of 5% ACN/0.1% TFA. The peptides were
injected into a C18 column equilibrated with 0.1% TFA with a linear
ACN/0.1% gradient at a flow rate of 0.2 ml/min, and 100 ll frac-
tions were collected. The major eluted peptides were analysed on
OrbiTrap Velos LCMS system. To determine the phosphorylated
residue in each [c32P]-labelled peptide, the peptides were immo-
bilised on a Sequelon-AA membrane and subjected to solid-phase
Edman degradation as described previously [65].
RNA interference (RNAi)
U2OS cells were seeded at ~1 × 105 cells per well in 6-well cell
culture plates. Cells were transfected with 5, 10 or 20 nM of the rele-
vant small interfering RNA (siRNA) oligonucleotides using 4 ll
Lipofectamine RNAiMAX (Invitrogen) or TransFectin (Bio-Rad) per
well in Opti-MEM reduced serum medium (Gibco). After 16 h, the
transfection media were removed and replaced with normal DMEM
culture medium. Cells were lysed 48 h post-transfection. All siRNA
oligonucleotides were purchased from Dharmacon (Product refs: J-
003957-13, J-003957-14, J-003957-15, J003957-16).
Statistical analysis
Data are presented as mean  standard error of the mean. Statisti-
cal significances of differences between experimental groups were
assessed using two-way ANOVA with post hoc Bonferroni
correction, unless stated differently in figure legends, using Prism6
software. Differences in means were considered significant if
P < 0.05.
Expanded View for this article is available online.
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